Sign up
Pharma Capital

Helix Biopharma shares rise despite posting $1.9 million loss in fiscal fiscal 2Q

The company is spending $1.3 million on research and development for its innovative cancer therapy
Lab tech looking in a microscope
The biopharmaceutical company is currently conducting Phase I trials for its cancer-fighting drug

Helix Biopharma Corp (TSE:HBP) pushed ahead its research-and-development spending in the fiscal second quarter of 2019, despite recording a net loss of $1.9 million, according to financial results released Monday.

The company posted a net loss of $1.9 million, or $0.02 loss per common share, in the three months ended January 31, compared with a $2.6 million, or $0.03 loss, a year earlier.

Shares of Helix rose $0.03 on Monday to $0.54, a gain of 5.9%.

READ: Leap Therapeutics shares pop thanks to promising trial for cancer drug DKN-01

Helix, a clinical-stage biopharmaceutical company that is developing innovative therapies for cancer treatment, spent $1.3 million in research and development in fiscal 2Q and $2.3 million for the six-month period, the bulk of which was directed toward its L-DOS47 technology, which promises to act upon naturally-occurring substances in the human body to treat cancer.

The company spent $788,000 in the quarter, primarily on its Phase 1 clinical study in the US. It also conducting clinical studies in Poland, Ukraine and Hungary.

The Polish subsidiary, which is focusing on the V-DOS47 clinical program, spent $102,000 and $232,000 over the three-month period ending January 2019 and 2018, respectively. Grant-funding for the V-DOS4 program is the result of an agreement with the Polish National Centre for Research and Development.

Helix also reported a working capital deficiency of $2 million, a shareholders’ deficiency of $1.7 million and a deficit of $167 million. The company’s cash reserves of $306,000 are insufficient to meet its working capital and capital expenditures for the next 12 months, as well as its R&D expenditures, it reported.

--Contact Angela Harmantas at [email protected]

--Follow her on Twitter @AHarmantas



Register here to be notified of future HBP Company articles
View full HBP profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.